Bardoxolone (CDDO, RTA 401) is a Nrf2 activator. Bardoxolone shows anti-SARS-CoV-2 3CLpro with IC50 of 27.99 µM. Bardoxolone activates the Nrf2 pathway and inhibits the NF-kappaB pathway. Bardoxolone can induce cells differentiation, apoptosis and shows antiproliferative activity against cancer cells. Bardoxolone can increase ROS and decrease intracellular GSH levels. Bardoxolone inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis. Bardoxolone can be used for the research of cancer, inflammation and infection, such as SARS-CoV infection and glioblastoma[1][2][3].
Molecular Weight:
491.66
Purity:
99.50
CAS Number:
[218600-44-3]
Formula:
C31H41NO4
Target:
Apoptosis,Glutathione Peroxidase,Keap1-Nrf2,Necroptosis,NF-kappaB,Reactive Oxygen Species (ROS),SARS-CoV
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
